PercuSense
PercuSense is dedicated to revolutionizing healthcare through intelligent biosensors that enable early detection, proactive intervention, and improved treatment of various health conditions. Their innovative continuous multi-analyte sensor system combines monitoring of multiple biosensors with knowledge of disease progression to proactively recommend treatment, aiming to enhance patient outcomes and safety.
Industries
Nr. of Employees
small (1-50)
PercuSense
28159 Avenue Stanford, Suite 190, Valencia, CA 91355
Patents
Products
Continuous multi-analyte biosensor system
A percutaneous, minimally invasive sensing system that provides continuous simultaneous measurements of multiple analytes (e.g., glucose and lactate) from a single subcutaneous probe and streams data for analytics.
On-body biosensor system for early chemical exposure detection
A wearable system that combines multi-analyte sensing (e.g., lactate, choline, tissue oxygen) with machine learning algorithms to detect and classify potential chemical exposure events in preclinical testing.
Continuous multi-analyte biosensor system
A percutaneous, minimally invasive sensing system that provides continuous simultaneous measurements of multiple analytes (e.g., glucose and lactate) from a single subcutaneous probe and streams data for analytics.
On-body biosensor system for early chemical exposure detection
A wearable system that combines multi-analyte sensing (e.g., lactate, choline, tissue oxygen) with machine learning algorithms to detect and classify potential chemical exposure events in preclinical testing.
Services
Sponsored development programs adapting multi-analyte biosensor platforms for defense and clinical applications, including preclinical validation and system miniaturization.
Design and execution of first-in-human feasibility testing and comparative benchmarking against venous reference methods and commercial continuous monitors.
Prototyping, microelectronics assembly, and supporting transfer of devices from development into production-scale manufacturing.
Sponsored development programs adapting multi-analyte biosensor platforms for defense and clinical applications, including preclinical validation and system miniaturization.
Design and execution of first-in-human feasibility testing and comparative benchmarking against venous reference methods and commercial continuous monitors.
Prototyping, microelectronics assembly, and supporting transfer of devices from development into production-scale manufacturing.
Expertise Areas
- Continuous metabolic monitoring
- Multi-analyte electrochemical sensor development
- Wearable and on-body system miniaturization
- Machine learning for biosignal classification and scoring
Key Technologies
- Electrochemical multi-analyte sensing
- Percutaneous subcutaneous probe technology
- Continuous glucose monitoring techniques
- Continuous lactate monitoring
News & Updates
PercuSense’s CEO, Brian Kannard, will be at the Chemical and Biological Defense Science and Technology (CBD S&T) conference giving an oral presentation to unveil exciting new data from the ChemWatch system. For the first time, we will present in vivo data demonstrating the sensor’s ability to detect simulated warfare agents.
PercuSense will present at the 24th Annual Diabetes Technology Meeting on October 15th-17th. PercuSense will present a poster titled “Feasibility of Multi-Metabolic Continuous Monitoring: Atlas HealthTM, A Roadmap to Improving Metabolic Health” covering recent advancements in the glucose and lactate sensor and the promise of lactate as a key metabolic analyte.
PercuSense Inc. shares the results of a clinical evaluation of the first-ever percutaneous multi-analyte CGM system. The device combines glucose and lactate sensors on a single probe for simultaneous, continuous measurements. The study demonstrated the feasibility of the sensor system with positive performance metrics.
PercuSense shares groundbreaking first-in-human study results of a multi-analyte sensor combining glucose and lactate. The study involved 11 participants with Type 1 diabetes and compared sensor data with venous blood values, demonstrating comparable performance and no interference between sensors.
PercuSense will exhibit and present at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy, and online. The presentation will include results from first-in-human testing of their novel glucose + lactate sensor.
PercuSense has started the fourth phase of collaboration with the Defense Threat Reduction Agency (DTRA) and Defense Innovation Unit (DIU) to develop a biosensor platform for early detection of chemical warfare agents, focusing on detection capabilities, miniaturization, and usability.
PercuSense’s CEO, Brian Kannard, will be at the Chemical and Biological Defense Science and Technology (CBD S&T) conference giving an oral presentation to unveil exciting new data from the ChemWatch system. For the first time, we will present in vivo data demonstrating the sensor’s ability to detect simulated warfare agents.
PercuSense will present at the 24th Annual Diabetes Technology Meeting on October 15th-17th. PercuSense will present a poster titled “Feasibility of Multi-Metabolic Continuous Monitoring: Atlas HealthTM, A Roadmap to Improving Metabolic Health” covering recent advancements in the glucose and lactate sensor and the promise of lactate as a key metabolic analyte.
PercuSense Inc. shares the results of a clinical evaluation of the first-ever percutaneous multi-analyte CGM system. The device combines glucose and lactate sensors on a single probe for simultaneous, continuous measurements. The study demonstrated the feasibility of the sensor system with positive performance metrics.
PercuSense shares groundbreaking first-in-human study results of a multi-analyte sensor combining glucose and lactate. The study involved 11 participants with Type 1 diabetes and compared sensor data with venous blood values, demonstrating comparable performance and no interference between sensors.
PercuSense will exhibit and present at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy, and online. The presentation will include results from first-in-human testing of their novel glucose + lactate sensor.
PercuSense has started the fourth phase of collaboration with the Defense Threat Reduction Agency (DTRA) and Defense Innovation Unit (DIU) to develop a biosensor platform for early detection of chemical warfare agents, focusing on detection capabilities, miniaturization, and usability.